Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

• Status: Terminated
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Danish Oncological Lung Cancer Group
• Treatments: Carboplatin; Cisplatin; Etoposide; Etoposide phosphate; Topotecan

Criteria

Inclusion Criteria:

• Histologically confirmed SCLC

• Extensive stage

• No prior chemotherapy

• WHO PS 0-3

• Adequate organ function (liver, kidney)

• Adequate hematology (bone marrow)

• Informed consent

Exclusion Criteria:

• PS 4

• Inadequate organ function

• Uncontrolled infection

• Concomitant major medical contraindications